Lexeo Therapeutics, Inc. Common Stock
Financials
Valuation Metrics
Lexeo Therapeutics, Inc. Common Stock's Market Cap is $345M. At end of 2025 it was $606M. Ranked #2914 of 3,121 in US market (top 93%), #1309 of 1,463 on NASDAQ (top 89%), #238 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $345M | US#2,914/3,121 Sec#238/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-87M | US—/3,121 Sec—/266 |
| Total Assets | $255M | US#2,952/3,121 Sec#225/266 |
| Net Assets | $235M | US#2,629/3,121 Sec#176/266 |
| Employees | 59 | US#2,700/3,121 Sec#206/266 |
| Value | ||
| P/B | 1.47x | US#843/3,121 Sec#34/266 |
| FCF Yield | -25.74% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -37.12% | US#2,611/3,121 Sec#126/266 |
| ROA | -34.24% | US#2,913/3,121 Sec#168/266 |
| Financial Health | ||
| Debt Ratio | 8.44% | US#86/3,121 Sec#39/266 |
| Total Debt | $7M | US#2,875/3,121 Sec#211/266 |
| FCF | $-89M | US#2,616/3,121 Sec#136/266 |
| Cash | $93M | US#2,273/3,121 Sec#182/266 |
| Current Ratio | 13.89x | US#183/3,121 Sec#55/266 |
| Performance | ||
| 1Y Return | -23.08% | US#2,446/3,121 Sec#213/266 |
| 1M Return | -21.79% | US#2,815/3,121 Sec#219/266 |
| From 52W High | -61.78% | US#2,931/3,121 Sec#237/266 |
| 1Y MDD | -61.15% | US#2,806/3,121 Sec#217/266 |
| Trading | ||
| Volume | 2,020,278 shares | US#1,353/3,121 Sec#144/266 |
| Trading Value | $8M | US#2,709/3,121 Sec#227/266 |
| Per Share | ||
| EPS | $-1.06 | US—/3,121 Sec—/266 |
| BPS | $2.87 | US#2,508/3,121 Sec#165/266 |
Company Info
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.